Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Leukemia
•
Hematology
How long do you continue ATRA during induction in high risk acute promyelocytic leukemia?
Does bone marrow biopsy done at the end of induction factor into your decision?
Related Questions
How long do you continue ursodiol for VOD prophylaxis after gemtuzumab ozogamicin for good-risk AML
Can AMPLIFY data be extrapolated to use of other BTKi's in combination with venetoclax or would you only ever use acalabrutinib/venetoclax in first line?
Does treating CLL reduce the risk of non-melanoma skin cancers?
How would you treat a patient with selective IgM deficiency on IVIG infusions with a new diagnosis of CLL?
In patients with post-PV myelofibrosis who are ineligible for allogeneic stem cell transplant, how do you approach symptomatic splenomegaly refractory to splenic radiation and ruxolitinib?
In treatment naive CLL without del(17p)/TP53, will the recent interim analysis of fixed duration acalabrutinib plus venetoclax +/- obinutuzumab vs chemoimmunotherapy in the AMPLIFY trial change your practice?
In an elderly transplant ineligible IDH1-mutated patient with AML, who is in remission after 6 cycles of azacitidine and ivosidenib, would you discontinue azacitidine after cycle 6 and continue maintenance ivosidenib until progression/toxicity or continue both azacitidine and ivosidenib?
What is your preferred first-line treatment regimen for patients with high-risk MDS?
How do you treat patients with T-cell ALL/T-cell lymphoblastic lymphoma who have pre-existing CKD with a CrCl of 30 mL/min or less?
Is there therapeutic relevance for FLT3-ITD mutation in relapsed APML?